为您找到相关结果约500个

你是不是要搜索 期刊首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动 点击跳转

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)

YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate

Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal

silico methods in identifying mechanisms of action and key components of anti-cancer herbal formulation YIV-906 (PHY906)

YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint

A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib

YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against

906 Schistosomiasis: The New 'Gap Year' Problem

Phosphate reabsorption in the kidney: NaPi-IIb or not IIb

Wray 15-906: a candidate luminous blue variable discovered with WISE, Herschel, and SALT

IGF-1 receptor inhibitor OSI-906 reduces growth in nestlings of a wild passerine

Bridging between Type IIb and Ib Supernovae: SN IIb 2022crv with a Very Thin Hydrogen Envelope

Phakomatosis pigmentovascularis type IIb

Mechanical circulatory support in high-risk percutaneous coronary intervention: IIb or not IIb?

Physical Activities in Northern Song Dynasty (906-1127), China: A Painting Analysis

为您找到相关结果约500个

共500条页码: 1/34页15条/页